Qualitative and quantitative assessment of endpoints in clinical trials

Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45: 228–247, 2009.Google Scholar

Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol, 25: 579–586, 2007.Google Scholar

Saad ED and Katz A. (2009). Progression-free survival and time to progression as primary end points in advanced breast cancer: often used sometimes loosely defined. Ann Oncol 20: 460–464 CrossRefPubMedGoogle Scholar

Sargent DJ, Patiyil S, Yothers G, et al. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol, 2007: JCO.2006.2010.4323.Google Scholar

Broglio KR and Berry DA. (2009). Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 101: 1642–1649 CrossRefPubMedGoogle Scholar

Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS and Baum M. (2008). Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9: 45–53 CrossRefPubMedGoogle Scholar

Saad ED, Katz A, Hoff PM and Buyse M. (2009). Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. Ann Oncol 21: 7–12 CrossRefPubMedGoogle Scholar